10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
62.65
-0.57 (-0.90%)
At close: Sep 4, 2026, 4:00 PM EDT
62.39
-0.26 (-0.42%)
After-hours: Sep 4, 2026, 7:30 PM EDT
10x Genomics Revenue
10x Genomics had revenue of $151.04M in the quarter ending June 30, 2026, a decrease of -12.65%. This brings the company's revenue in the last twelve months to $616.91M, down -4.28% year-over-year. In the year 2025, 10x Genomics had annual revenue of $642.82M with 5.25% growth.
Revenue (ttm)
$616.91M
Revenue Growth
-4.28%
P/S Ratio
13.23
Revenue / Employee
$523,694
Employees
1,178
Market Cap
8.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 642.82M | 32.04M | 5.25% |
| Dec 31, 2024 | 610.79M | -7.94M | -1.28% |
| Dec 31, 2023 | 618.73M | 102.32M | 19.81% |
| Dec 31, 2022 | 516.41M | 25.92M | 5.28% |
| Dec 31, 2021 | 490.49M | 191.65M | 64.13% |
| Dec 31, 2020 | 298.85M | 52.95M | 21.53% |
| Dec 31, 2019 | 245.89M | 99.58M | 68.06% |
| Dec 31, 2018 | 146.31M | 75.23M | 105.83% |
| Dec 31, 2017 | 71.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 14.37B |
| Veeva Systems | 3.46B |
| Privia Health Group | 2.36B |
| Tempus AI | 1.43B |
| HealthEquity | 1.36B |
| Omnicell | 1.25B |
| Waystar Holding | 1.21B |
| Hinge Health | 720.06M |
TXG News
- 5 days ago - 10x Genomics initiated with a Sector Perform at RBC Capital - TheFly
- 8 days ago - 10x Genomics reports patent infringement win against Parse Biosciences - TheFly
- 8 days ago - 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences - PRNewsWire
- 20 days ago - 10x Genomics price target raised to $65 from $50 at Stephens - TheFly
- 27 days ago - 10x Genomics price target raised to $60 from $50 at Canaccord - TheFly
- 27 days ago - 10x Genomics price target raised to $47 from $42 at Piper Sandler - TheFly
- 4 weeks ago - 10x Genomics price target raised to $40 from $37 at Morgan Stanley - TheFly
- 4 weeks ago - 10x Genomics price target raised to $50 from $25 at Stifel - TheFly